View Older Stories View More Recent Stories

Feb 15, 2019 06:45AM FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) as First-Line Treatment for Advanced Renal Cel
Feb 14, 2019 06:50AM Merck (MRK) Increases Focus on Advanced Prostate Cancer, Expanding Immuno-Oncology Program with Three New Phase 3 Trials
Feb 14, 2019 06:45AM Merck Increases Focus on Advanced Prostate Cancer, Expanding Immuno-Oncology Program with Three New Phase 3 Trials
Feb 11, 2019 05:45PM EMD Seron, Pfizer (PFE) Announce FDA Accepted sBLA and Granted Priority Review for BAVENCIO Plus INLYTA for Treatment of Advanced RCC
Feb 11, 2019 05:44PM FDA Accepts sBLA and Grants Priority Review for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) for the Treatment of Advanced Renal Cell Carcinoma
Feb 11, 2019 05:03PM Merck (MRK) Highlights Breadth of Immuno-Oncology Research Program in Genitourinary Cancers at ASCO GU
Feb 11, 2019 05:02PM Merck Highlights Breadth of Immuno-Oncology Research Program in Genitourinary Cancers at ASCO GU
Feb 11, 2019 06:46AM Merck (MRK) Says FDA Granted Priority Review to its sBLA for KEYTRUDA for First-Line Treatment of Patients with Recurrent or Metastatic HNSCC
Feb 11, 2019 06:45AM FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Patients with Recurrent or Metastatic Head and Neck Sq
Feb 5, 2019 06:50AM Merck (MRK) Says FDA Accepted for Review NDA for its Investigational Combination of Imipenem/Cilastatin and Relebactam, and sNDA for ZERBAXA
Feb 5, 2019 06:45AM FDA Accepts for Review New Drug Application (NDA) for Merck’s Investigational Combination of Imipenem/Cilastatin and Relebactam, and Supplemental NDA (sNDA) for ZERBAXA® (Ceftolozane and Tazobactam
Feb 4, 2019 06:48AM Merck (MRK) Reports EMA's CHMP Adopts Positive Opinion for Merck’s KEYTRUDA (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Adults with Metastatic Squamous NSCLC
Feb 4, 2019 06:45AM European Medicines Agency Adopts Positive Opinion for Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Adults with Metastatic Squamous Non-Small Cell L
Feb 1, 2019 06:45AM Merck Announces Fourth-Quarter and Full-Year 2018 Financial Results
Jan 30, 2019 06:46AM Merck (MRK) Receives Breakthrough Therapy Designation from FDA for V114 for Prevention of IPD in Children
Jan 30, 2019 06:45AM Merck Receives Breakthrough Therapy Designation from FDA for V114, the Company’s Investigational 15-Valent Conjugate Vaccine for the Prevention of Invasive Pneumococcal Disease, in Infants, Children
Jan 29, 2019 04:31PM Merck (MRK) Reports Election of Mary Ellen Coe to Board
Jan 29, 2019 04:30PM Mary Ellen Coe Elected to Merck Board of Directors
Jan 29, 2019 03:08PM Merck Announces Second-Quarter 2019 Dividend
Jan 22, 2019 06:45AM Merck to Hold Fourth-Quarter and Full-Year 2018 Sales and Earnings Conference Call on February 1
Jan 14, 2019 05:01PM Merck's (MRK) KEYTRUDA Reduced Risk of Death by 31% Compared to Chemotherapy in Previously Treated Patients with Advanced Esophageal or Esophagogastric Junction Carcinoma
Jan 14, 2019 05:00PM Merck’s KEYTRUDA® (pembrolizumab) Reduced Risk of Death by 31 Percent Compared to Chemotherapy in Previously Treated Patients with Advanced Esophageal or Esophagogastric Junction Carcinoma Whose Tu
Jan 3, 2019 06:53AM Merck (MRK) Announces Five New Approvals for KEYTRUDA (pembrolizumab) in Japan, Including 3 Expanded Uses in Advanced NSCLC
Jan 3, 2019 06:45AM Merck’s KEYTRUDA® (pembrolizumab) Receives Five New Approvals in Japan, Including in Advanced Non-Small Cell Lung Cancer (NSCLC), as Adjuvant Therapy for Melanoma, and in Advanced Microsatellite In
Jan 3, 2019 06:34AM Merck (MRK) Exercises Option to License NGM313, for Treatment of NASH & Type 2 Diabetes
Jan 3, 2019 06:30AM Merck Exercises Option for NGM Bio’s Investigational Insulin Sensitizer, NGM313, for the Treatment of NASH and Type 2 Diabetes
Jan 2, 2019 06:45AM Merck to Participate at the 37th Annual J.P. Morgan Healthcare Conference
Dec 21, 2018 02:06PM UPDATE: Merck KGaA, Pfizer (PFE) to Terminate JAVELIN Ovarian 100 Trial of Avelumab
Dec 21, 2018 02:00PM Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on JAVELIN Ovarian 100 Trial of Avelumab in Previously Untreated Advanced Ovarian Cancer
Dec 20, 2018 04:27PM Merck (MRK) Reports Extended Action Date on KEYTRUDA (pembrolizumab) Supplemental Biologics License Application (sBLA) for KEYNOTE-042 Trial
Dec 20, 2018 04:15PM Merck Provides Update on KEYTRUDA® (pembrolizumab) Supplemental Biologics License Application (sBLA) for KEYNOTE-042 Trial
Dec 20, 2018 06:31AM Merck (MRK) Reports LYNPARZA (olaparib) Meets Primary Endpoint in Phase 3 SOLO-3 Trial for Treatment of Relapsed BRCA-Mutated Advanced Ovarian Cancer
Dec 20, 2018 06:30AM LYNPARZA® (olaparib) Meets Primary Endpoint in Phase 3 SOLO-3 Trial for the Treatment of Relapsed BRCA-Mutated Advanced Ovarian Cancer
Dec 19, 2018 04:13PM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Adult and Pediatric Patients with Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma, a Rare Form of Skin Cancer
Dec 19, 2018 04:04PM AstraZeneca (AZN) and Merck (MRK) Reports LYNPARZA Approved by FDA for First-Line Maintenance Therapy in BRCA-mutated Advanced Ovarian Cancer
Dec 19, 2018 03:18PM Merck (MRK) Announces LYNPARZA Approved by FDA for First-Line Maintenance Therapy in BRCA-Mutated Advanced Ovarian Cancer
Dec 19, 2018 03:16PM LYNPARZA® (olaparib) Approved by FDA for First-Line Maintenance Therapy in BRCA-Mutated Advanced Ovarian Cancer
Dec 17, 2018 06:31AM Merck (MRK) Announces EC Approves its KEYTRUDA as Adjuvant Therapy for Adults with Resected Stage III Melanoma
Dec 17, 2018 06:30AM European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Adults with Resected Stage III Melanoma
Dec 14, 2018 06:46AM Merck (MRK) to Acquire Antelliq Group for EUR2.1 Billion Plus Debt
Dec 14, 2018 06:45AM Merck to Acquire Privately Held Antelliq Group
Dec 12, 2018 10:30AM Merck and Instituto Butantan Announce Collaboration Agreement to Develop Vaccines to Protect Against Dengue Infections
Dec 10, 2018 04:30PM Merck’s President of Global Human Health Adam H. Schechter to Leave Merck Frank Clyburn Named Chief Commercial Officer and Michael Nally Named Chief Marketing Officer
Dec 10, 2018 11:30AM MilliporeSigma and genOway Form CRISPR/Cas9 Strategic Alliance to Develop Rodent Models
Dec 3, 2018 06:45AM Merck to Present at the Citi 2018 Global Healthcare Conference
Nov 28, 2018 04:32PM Merck (MRK) says EC Approved DELSTRIGO and PIFELTRO for Treatment of HIV-1 Infection
Nov 28, 2018 04:30PM European Commission Approves Merck’s DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and PIFELTRO™ (doravir
Nov 27, 2018 08:00AM MilliporeSigma Wins Two R&D 100 Awards for Innovation in 2018
Nov 19, 2018 07:12AM Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer
Nov 15, 2018 09:01AM NewLink Genetics (NLNK) Says Merck (MRK) Has Begun Rolling Submission of Licensure Application for Ebola vaccine V920 to FDA
View More Recent Stories View Older Stories